Hikma Pharmaceuticals Plc Stock Rating Reaffirmed by Barclays (HIK)
Hikma Pharmaceuticals Plc (LON:HIK) traded down 2.17% on Friday, hitting GBX 1760.00. 275,642 shares of the company’s stock traded hands. Hikma Pharmaceuticals Plc has a 52 week low of GBX 1004.00 and a 52 week high of GBX 1835.00. The stock has a 50-day moving average of GBX 1725. and a 200-day moving average of GBX 1553.. The company’s market cap is £3.481 billion.
A number of other firms have also recently commented on HIK. Analysts at Jefferies Group raised their price target on shares of Hikma Pharmaceuticals Plc from GBX 1,600 ($27.17) to GBX 1,610 ($27.34) in a research note on Friday. They now have a “hold” rating on the stock. Separately, analysts at Goldman Sachs upgraded shares of Hikma Pharmaceuticals Plc to a “buy” rating in a research note on Friday, July 18th. They now have a GBX 2,250 ($38.21) price target on the stock, up previously from GBX 1,800 ($30.57). Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, June 17th. They now have a GBX 1,400 ($23.77) price target on the stock. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of GBX 1,698.57 ($28.84).
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.